Article
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
The Journal of investigative dermatology - 1 Apr 2007
Liu Wendy, Kelly John W, Trivett Melanie, Murray William K, Dowling John P, Wolfe Rory, Mason Graham, Magee Jill, Angel Christopher, Dobrovic Alexander, McArthur Grant A
Abstract excerpt
The BRAF(T1799A) mutation encodes BRAF(V600E) that leads to activation of the mitogen-activated protein kinase pathway. This study aimed to assess the clinico-pathological features of primary invasive melanomas containing the BRAF(T1799A) mutation. Patients (n=251) with invasive primary melanomas from Australia were interviewed and examined with respect to their melanoma characteristics and risk factors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.